- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02142998
A Prospective Blinded Randomized Study Comparing Laparoscopic Sleeve Gastrectomy and Laparoscopic Roux-en-y Gastric Bypass and Their Effect on Gastro-Esophageal Reflux Disease Using 24 Horus pH Monitoring (GERD)
April 25, 2017 updated by: Mehran Anvari, McMaster University
Obesity has become a significant health problem in Canada.
It is known to be a risk factor for many diseases, including Gastro-Esophageal Reflux Disease (GERD).
When medical efforts to lose weight fail, patients often consider bariatric surgical procedures as the next step.
The two most common bariatric procedures performed are Roux-en-Y Gastric Bypass (LRYGB) and Laparoscopic Sleeve Gastrectomy (LSG).
The gold standard for diagnosing GERD is Esophageal pH monitoring, as it is the most objective method to document the reflux, assess the severity and monitor the response to treatment of the disease.
In the last few years LSG has gained in popularity due to its simplicity and short operative time.
Currently the comparison between bariatric surgery and GERD symptoms is very one sided.
There are significant numbers of studies with conclusive results that state that LRYGB has a positive effect on GERD symptoms, however there is little evidence that states the same about LSG.
This means that the relationship between LSG and GERD is inconclusive.
An objective evaluation of GERD using 24 hour pH monitoring and validated CRFs at different follow up time points will contribute greatly to our understanding of what this relationship might be.
Study Overview
Status
Suspended
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
100
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ontario
-
Hamilton, Ontario, Canada, L8N 4A6
- St. Joseph's Healthcare
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Fulfilled criteria for bariatric surgery as coined by National Institutes of Health conference.
- Their age is ≥18 years and ≤70 years
- The group with symptoms of GERD needs to have diagnosis of GERD in their medical record and taking proton pump inhibitors on a daily basis.
- Able and willing to give written consent
- The patient is willing to perform the pre-operative tests required for this study.
- The patient fits for both surgeries - LSG or LRYGB
Exclusion Criteria:
- Previous bariatric surgery
- Previous anti reflux procedure
- Contra-indication to general anesthesia
- Any medical condition, which in the judgment of the Investigator and/or designee makes the subject a poor candidate for the investigational procedure
- Pregnant or lactating female (Women of child bearing potential must take a pregnancy test prior to surgery)
- Hiatal hernia above 4cm (measured in the pre-operative gastroscopy).
- Multiple surgeries in abdominal cavity or previous small bowel disease/resection
- Patient on CPAP treatment for his OSA disease
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: OTHER
- Allocation: RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
ACTIVE_COMPARATOR: GERD Symptoms
|
The study is performed with the patient fasting for a minimum of 6 hours.
A single channel or dual channel (15 cm spacing) pH probe is inserted trans nasally.
The pH sensor, or distal pH sensor in the case of 2 channel testing, is positioned 5 cm above the proximal margin of the LES, as determined by esophageal manometric testing.
pH-Z ambulatory monitor (Given Imaging Digitrapper) is used for data acquisition and the data analyzed with pH Analysis Program (Given Imaging AccuView).
The number of reflux events, defined as a drop in esophageal pH readings below 4.0, is recorded and the percentage of time with esophageal acid exposure is analyzed using defined protocols and accepted normal values.
A high resolution esophageal manometry catheter is used for testing and inserted Trans nasally.
The patient is given 10 liquid swallows (5mL of water), at intervals of approximately 30 seconds.
The catheter (Sierra Scientific/Given Imaging) has 36 sensors, each one averaging pressures from 12 circumferential positions.
This gives a total of 432 data points.
The sensors are placed 1 cm apart, spanning a length of 35 cm.
The catheter simultaneously records pressure readings from the esophagus, sphincter regions (UES and LES), pharynx and stomach without the need for a station pull-through technique.
Results are reported according to defined protocols and accepted normal values.
|
|
ACTIVE_COMPARATOR: No GERD Symptoms
|
The study is performed with the patient fasting for a minimum of 6 hours.
A single channel or dual channel (15 cm spacing) pH probe is inserted trans nasally.
The pH sensor, or distal pH sensor in the case of 2 channel testing, is positioned 5 cm above the proximal margin of the LES, as determined by esophageal manometric testing.
pH-Z ambulatory monitor (Given Imaging Digitrapper) is used for data acquisition and the data analyzed with pH Analysis Program (Given Imaging AccuView).
The number of reflux events, defined as a drop in esophageal pH readings below 4.0, is recorded and the percentage of time with esophageal acid exposure is analyzed using defined protocols and accepted normal values.
A high resolution esophageal manometry catheter is used for testing and inserted Trans nasally.
The patient is given 10 liquid swallows (5mL of water), at intervals of approximately 30 seconds.
The catheter (Sierra Scientific/Given Imaging) has 36 sensors, each one averaging pressures from 12 circumferential positions.
This gives a total of 432 data points.
The sensors are placed 1 cm apart, spanning a length of 35 cm.
The catheter simultaneously records pressure readings from the esophagus, sphincter regions (UES and LES), pharynx and stomach without the need for a station pull-through technique.
Results are reported according to defined protocols and accepted normal values.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Observe acid exposure to the distal esophagus
Time Frame: 1 year
|
This will be measured using the esophageal 24 hours monitoring before surgery and at the 6 month follow up.
The patients will be randomized to two different types of surgery and the results compared.
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Compare GERD symptoms in patients.
Time Frame: 1 year
|
This will be measured using esophageal manometry prior to surgery and at the six month follow up visit.
We are looking for time in minutes with a pH of below 4 and a Demeeser score of below 14.7
|
1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2014
Primary Completion (ANTICIPATED)
December 1, 2018
Study Completion (ANTICIPATED)
December 1, 2018
Study Registration Dates
First Submitted
March 24, 2014
First Submitted That Met QC Criteria
May 16, 2014
First Posted (ESTIMATE)
May 20, 2014
Study Record Updates
Last Update Posted (ACTUAL)
April 26, 2017
Last Update Submitted That Met QC Criteria
April 25, 2017
Last Verified
April 1, 2017
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 14-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on GERD
-
Baylor Research InstituteRecruiting
-
Ohio State UniversityCompleted
-
Chong Kun Dang PharmaceuticalCompleted
-
Chong Kun Dang PharmaceuticalRecruiting
-
Cinclus Pharma Holding ABCompleted
-
Korea United Pharm. Inc.CompletedGERDKorea, Republic of
-
Korea United Pharm. Inc.Completed
-
Chong Kun Dang PharmaceuticalUnknown
-
Turku University HospitalCompleted
Clinical Trials on 24 pH monitoring
-
Vanderbilt University Medical CenterTerminatedIdentify Normal MII-pH ParametersUnited States
-
Asian Institute of Gastroenterology, IndiaRecruitingEsophageal Diseases | Esophagitis | Reflux DiseaseIndia
-
Assiut UniversityUnknownIrritable Bowel Syndrome | GERD | Non-erosive Reflux Disease | Functional Esophageal Disorders
-
The Functional Gut ClinicRosa BiotechRecruiting
-
Ivashkin Vladimir TrofimovichAbbottCompletedGastroesophageal Reflux Disease (GERD)Russian Federation
-
University Hospital OstravaUniversity Hospital Bratislava; Fortmedica PragueCompletedExtraesophageal Reflux | Inferior Nasal Turbinate HypertrophyCzechia, Slovakia
-
Medtronic - MITGCompletedGastro Esophageal Reflux DiseaseIsrael
-
Assistance Publique - Hôpitaux de ParisCompleted
-
University Hospital OstravaCompletedNasal Polyps | Laryngopharyngeal Reflux | Nasal DiseasesCzech Republic
-
Southern Arizona VA Health Care SystemUnknownGastroesophageal Reflux DiseaseUnited States